Skip to main content
TIANYU BIO-TECHNOLOGY CO.,LTD. logo

TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603717 ISIN · CNE1000030W1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2025-04-15 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603717

About TIANYU BIO-TECHNOLOGY CO.,LTD.

https://www.tianyubiotech.com/

TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.

Recent filings

Filing Released Lang Actions
关于公司2024年度利润分配预案的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's 2024 profit distribution plan. It states that due to a net loss, no profit distribution or capital reserve conversion to shares will occur. The announcement includes details about the board and supervisory committee approvals and mentions that the plan will be submitted to the 2024 annual shareholders meeting for approval. The document is relatively short (1970 characters) and primarily serves as a notice of the profit distribution proposal rather than the full annual report or financial statements. It does not contain comprehensive financial data or detailed financial performance analysis. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an official announcement related to corporate actions but not a full financial report or earnings release.
2025-04-15 Chinese
关于召开2024年度业绩说明会暨问题征集的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2024 annual performance explanation meeting (业绩说明会) for Tianyu Bio-Technology Co., Ltd. It mentions the date, time, location, participants, and how investors can participate and ask questions. It also references that the 2024 annual report has already been published on April 16, 2025, and this meeting is to explain and discuss the results. The document does not contain actual financial statements or detailed financial data but is an announcement of an investor presentation event focused on discussing the annual results. Therefore, it fits the category of Investor Presentation (IP) rather than the Annual Report (10-K) or Earnings Release (ER). The document length is short (1429 characters), and it is clearly an announcement of a meeting for performance explanation and Q&A, which aligns with the Investor Presentation category.
2025-04-15 Chinese
中德证券有限责任公司关于天域生物科技股份有限公司2024年度募集资金存放与使用情况的核查意见
Regulatory Filings
2025-04-15 Chinese
德恒上海律师事务所关于天域生物科技股份有限公司2022年股票期权激励计划首次授予部分第三个行权期及预留授予部分第二个行权期行权条件未成就、注销部分已授予尚未行权的股票期权的法律意见书
Regulatory Filings
2025-04-15 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled "天域生物科技股份有限公司2024 年年度报告" which translates to "Tianyu Bio-Technology Co., Ltd. 2024 Annual Report." It contains detailed financial data for the fiscal year 2024, including revenue, net profit, cash flow, and other financial indicators. The document also includes management discussion and analysis, company information, accounting policies, and audit opinions. The presence of a standard unqualified audit report by an accounting firm is mentioned, and the report covers the full fiscal year from January 1, 2024, to December 31, 2024. The length of the document is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. These characteristics align with the definition of an Annual Report (10-K), which is an official yearly report covering company activity and full financial performance. FY 2024
2025-04-15 Chinese
2024年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2024年度董事会审计委员会履职情况报告" which translates to "2024 Annual Report on the Board Audit Committee's Performance." It details the audit committee's activities, meetings, supervision of external and internal audits, review of financial reports, internal control evaluations, and overall assessment for the year 2024. The content focuses on the audit committee's work and oversight rather than presenting the full annual financial report itself. The document length is 2767 characters, which is relatively short and more consistent with a committee report rather than a full Annual Report (10-K). It is not a certification or a brief announcement but a detailed committee report on audit activities and governance. This fits best under Audit Report / Information (AR), which includes standalone audit reports and related oversight information, excluding full Annual Reports. Therefore, the classification is AR with high confidence. FY 2024
2025-04-15 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.